Multiple sclerosis is increasingly being recognized as a neurodegenerative disease that is triggered by in¯am-matory attack of the CNS. As yet there is no satisfactory treatment. Using experimental allergic encephalomyelitis (EAE), an animal model of multiple sclerosis, we demonstrate that the cannabinoid system is neuroprotective during EAE. Mice de®cient in the cannabinoid receptor CB 1 tolerate in¯ammatory and excitotoxic insults poorly and develop substantial neurodegeneration following immune attack in EAE. In addition, exogenous CB 1 agonists can provide signi®cant neuroprotection from the consequences of in¯ammatory CNS disease in an experimental allergic uveitis model. Therefore, in addition to symptom management, cannabis may also slow the neurodegenerative processes that ultimately lead to chronic disability in multiple sclerosis and probably other diseases.
Introduction
Multiple sclerosis is a chronic disease of the CNS, where autoimmunity is thought to drive the development of in¯ammatory lesions that induce the primary demyelination, which results in the inhibition of normal neurotransmission (Compston and Coles, 2002) . However, the observation that disability often continues to worsen despite immunotherapy, which reduces blood±brain barrier dysfunction and relapse rate (Coles et al., 1999; SPECTRIMS Study Group, 2001; Wiendl and Hohlfeld, 2002) underscores that neurodegenerative changes are of major importance in disease progression (Barnes et al., 1991; Ferguson et al., 1997; Trapp et al., 1998; Coles et al., 1999) . This correlates with gross atrophy of the CNS, axonal loss and the accumulation of permanent disability (Bjartmar et al., 2000; Compston and Coles, 2002) . Axonal pathology is an early feature of multiple sclerosis lesions and is initially associated with in¯ammation (De Stefano et al., 2001; Filippi et al., 2003) ; likewise, axonal damage is a feature in experimental allergic encephalomyelitis (EAE), an autoimmune model of multiple sclerosis (Baker et al., 1990; Wujek et al., 2002) . During multiple sclerosis and EAE, destruction of myelin results in the redistribution and aberrant expression of axonal ion channels, and demyelinated axons are particularly sensitive to the damaging effects of free-radicals and glutamate excitotoxicity, which may additionally contribute to chronic neurodegeneration in CNS autoimmune disease (Foster et al., 1980; Black et al., 2000; Pitt et al., 2000; Smith et al., 2000 Smith et al., , 2001 Werner et al., 2001; Lo et al., 2002; Kapoor et al., 2003) . Therapeutic strategies in multiple sclerosis have concentrated on immunomodulation (Wiendl and Hohl®eld, 2002) . There is an urgent need for agents that can inhibit progressive multiple sclerosis.
Cannabis contains many compounds but it has been found that the major psychoactive ingredient is D 9 -tetrahydrocannabinol (D 9 -THC) (Mechoulam and Gaoni, 1967) . D 9 -THC mediates the majority of its activities through stimulation of cannabinoid receptors (CB), notably CB 1 , which are expressed throughout the CNS (Matsuda et al., 1990; Howlett et al., 2002) . Following the discovery of the receptors, fatty acid endogenous ligands, such as anandamide and 2-arachidonoyl glycerol (2-AG), and a degradation system including a re-uptake mechanism and hydrolytic enzymes have been identi®ed (Devane et al., 1992; Deutsch and Chin, 1993; Mechoulam et al., 1995; Dinh et al., 2002) . The cannabinoid system functions to regulate synaptic neurotransmission (Kreitzer and Regehr, 2001; Wilson and Nicoll, 2001 ) and tonically controls clinical signs such as spasticity and tremor that develop in chronic EAE . This provides objective evidence to support the claims of multiple sclerosis patients that cannabis may have a bene®t in symptom management (Consroe et al., 1997) , a claim further supported by some recent clinical trials of medical cannabis extracts (Killestein et al., 2002; Robson et al., 2002; Vaney et al., 2002) . There is in vitro evidence that cannabinoids can also regulate glutamate release, oxidant free radicals and calcium in¯uxes (Twitchell et al., 1997; Hampson et al., 1998; Kreitzer and Regehr, 2001; Howlett et al., 2002) , which, in excess, can cause neuronal death in neuroin¯ammatory disease (Pitt et al., 2000; Smith et al., 2000; Kapoor et al., 2003) . The lack of speci®city of all available cannabinoid reagents (Howlett et al., 2002) and the potential presence of additional CB-like receptors (Di Marzo et al., 2000; Breivogel et al., 2001; Monory et al., 2002) means that gene-deleted transgenic mice (Ledent et al., 1999; Zimmer et al., 1999) provide powerful tools to de®nitively investigate the potential role of the cannabinoid system in neuroprotection.
Material and methods Animals
Biozzi ABH and CB1 gene (Cnr1)-de®cient mice were from stock bred at the Institute of Neurology. They were fed RM-1(E) diet and water ad libitum. Congenic (N5) ABH.Cnr1 ±/± ±/+ and +/+ were generated from CD1.Cnr1±/± knockout mice (Ledent et al., 1999) and screened as described previously (Brooks et al., 2002) . B10.RIII mice were purchased from Harlan Olac, Oxford, UK. All experiments were ethically performed according to the UK Animals (Scienti®c Procedures) Act (1984) , under the control of the UK Government, Home Of®ce.
Chemicals
The cannabinoid receptor agonists R(+)-WIN55,212 and CP55,940 were purchased from Tocris (Bristol, UK). Nmethyl-D-aspartate (NMDA) and the NMDA receptor antagonist MK-801 were obtained from Sigma (Poole, UK). The CB 1 selective antagonist rimonabant (SR141617A; Rinaldi-Carmona et al., 1994) and D 9 -THC were from the National Institute for Drugs and Abuse (NIDA) drug supply program. These were dissolved in ethanol : cremophor : PBS (1 : 1 : 18) and 0.1±0.2 ml was injected intraperitoneally (i.p.) daily.
Induction of chronic relapsing EAE (CREAE)
Mice were injected subcutaneously in the¯ank on day 0 and 7 with 1 mg mouse spinal cord homogenate in complete Freund's adjuvant [60 mg Mycobacterium tuberculosis H37Ra, Mycobacterium butyricum (4 : 1) per injection] on day 0 and 7 (Baker et al., 1990) . Clinical disease was assessed daily and scored: 0 = normal, 1 = limp tail, 2 = impaired righting re¯ex, 3 = paresis of hindlimbs, 4 = complete paralysis of hindlimbs and 5 = moribund/death (O'Neill et al., 1992) . The activity of animals was monitored over 5 min in a 27 Q 27 cm open-®eld activity chamber (Brooks et al., 2002) . Tissues were either snap-frozen or formaldehyde-®xed for immunohistology (Baker et al., 1990; Ahmed et al., 2002) , western blotting for caspase activity (Ahmed et al., 2002) and enzyme-linked immunosorbent assay (ELISA) detection of CNS proteins. The results represent the number of animals within a group that developed clinical EAE, the mean maximal clinical score T SEM that developed during acute phase EAE (up to day 24 post-inoculation) and the mean day of onset T SD of clinical EAE (score >0.5) The disease incidence, onset and severity of congenic mice was comparable (P > 0.05) to that found in wild-type ABH mice, as assessed using the Mann±Whitney U-test.
Neuro®lament ELISA
Whole spinal cords were homogenized on ice by trituration and sonication in 500 ml of barbitone buffer [11 mM barbital, 63 mM sodium barbital, 1.2 mM EDTA (Sigma)] containing a protease inhibitor cocktail and 4 mM EGTA. Lipids were extracted from the sample by adding diisopropyl-ether (Sigma) at 1 : 5000 and centrifuging for 5 min at 20 000 g. The supernatant was frozen and stored in aliquots at ±70°C, and the total protein was measured using the standard Lowry method. Ninety-six-well microtitre plates (Maxisorp; Nunc, Rochester, NY, USA) were coated overnight at 4°C with the SMI35 coat monoclonal antibody (SMI35; Sternberger Monoclonals Inc., Lutherville, MD, USA) against neuro®lament heavy chain diluted in 0.05 M sodium carbonate (pH 9.6). This was followed by a wash step with barbitone buffer containing 5 mM EDTA, 1% bovine serum albumin and 0.05% Tween-20 (Sigma). Nonspeci®c protein binding was blocked by incubation with 1% bovine serum albumin in barbitone buffer for 1 h at room temperature, followed by a wash with wash buffer as above. Spinal cord homogenates were serially diluted to 1 : 10 000 in barbitone buffer containing 5 mM EDTA, and incubated at room temperature for 2 h. After washing, a rabbit polyclonal anti-neuro®lament H antibody (N-4142; Sigma), diluted 1 : 1000, was incubated at room temperature for 1 h. Following another wash, horseradish peroxidase-conjugated anti-rabbit immunoglobulin diluted 1 : 1000 was incubated for 1 h at room temperature. The tetramethylbenzidine chromogenic reagent (R & D Systems Europe, Minneapolis, MN, USA) was used, signal development stopped using 1 M phosphoric acid, and the plate read at 450 nm, with a reference reading at 620 nm. The antigen concentration for each sample was calculated from an internal standard curve ranging from 0 to 250 ng/ml (high-performance liquid chromatography-puri®ed bovine neuro®lament H; Af®niti Bioreagents, Golden, Colorado, USA). All samples were analysed in duplicate.
Induction of experimental allergic uveitis (EAU)
B10.RIII mice were injected subcutaneously with 25 mg interphotoreceptor retinoid binding protein (IRBP1 51±181 ) peptide in complete Freund's adjuvant (as used in EAE experiments) on day 0 and 7, disease was assessed histologically, by haematoxylin and eosin-stained 5 mm paraf®n wax sections, for the level of in®ltration (score 0±6) and structural damage (score 0±5), as described previously (Hankey et al., 2001 ).
Glutamate excitotoxcity NMDA-induced Ca 2+ in¯ux
Cerebellar neurons obtained from 6-day-old wild-type ABH.Cnr1+/+ and CB 1 knockout mice were cultured for 9 days in poly-D-lysine coverslips as described previously (Evans and Pocock, 1999) . At 36 h and 6 days, 10 mM cytosine arabinoside was added to inhibit non-neuronal proliferation (Evans and Pocock, 1999) . Cells were loaded with 5 mM of the¯uorescent Ca 2+ indicator dye fura-2 acetoxymethyl ester (Calbiochem, Nottingham, UK), prior to ionotropic glutamate receptor stimulation with 100 mM NMDA and subsequent inhibition with the NMDA receptor antagonist, 10 mM MK-801. This concentration of MK-801 is required to give maximal block of imaged NMDAinduced Ca 2+ in¯uxes in cerebellar neurons (Pocock and Nicholls, 1998 
Kainic acid induced lesion
Mice were deeply anaesthetized with halothane and stereotactically injected unilaterally (bregma 2.5 mm, mediallateral 1.7 mm and dorsoventral 1.6 mm) with 1.5 nmol of kainic acid in 30 ml of 0.9% saline over 30 s; the injection needle was retained for 1 min to prevent re¯ux of¯uid (Chen and Strickland, 1997) .
Statistical analysis
Non-parametric data were assessed using the Mann±Whitney U-test with Minitab software (Coventry, UK), parametric data were assessed using t-tests with Sigmastat software. The group score represents the maximal clinical grade developed by all animals within the group. Cannabinoids mediate neuroprotection in experimental allergic encephalomyelitis. CREAE was actively induced in wild-type ABH or CB 1 gene (Cnr1)-de®cient, congenic ABH mice with mouse spinal cord homogenate in complete Freund's adjuvant on day 0 and 7, and disease progression in wild-type mice is associated with axonal damage and loss. (A) Spinal cord neuro®lament levels from tissue homogenates from wild-type (open boxes) and CB 1 knockout (shaded boxes) mice were measured by ELISA from normal and animals with EAE in remission after one or four paralytic disease episodes during EAE. The results represent the mean T SEM neuro®lament levels (n = 6±8 per group). **P < 0.01, ***P < 0.001 compared with respective normal controls. (B±E) Axonal damage was re¯ected histologically. Bielshowsky silver stain of paraf®n 5 mm wax sections of lumbar spinal cord in (B) normal and (C) chronic EAE after four attacks, demonstrating few surviving axons (arrows) and note the loss of axons in the dorsal horn. Neuro®lament-speci®c immunocytochemistry of the spinal cord from a CB 1 knockout mouse (D) before and (E) after a single paralytic episode of EAE. Note the many transactions of the white matter axons. (F) Caspase-1 and -3 levels were assessed using western analysis and caspase-3 levels are signi®cantly (P < 0.001) elevated in CB 1 knockout mice (shaded boxes) during acute EAE compared with wild type (open boxes) (Student's t-test; n = 6 per group).
Results

Development of chronic paresis in EAE is associated with accumulation of axonal loss
Following actively, spinal cord homogenate-induced CREAE, ABH mice develop a relapsing±remitting disease progression of distinct paralytic disease episodes followed by remission with an increasing residual de®cit (Baker et al., 1990 . Although histological axonal damage occurs in the initial acute phase of CREAE in ABH mice, this becomes much more evident, particularly in the spinal cord, following the development of relapsing disease (Baker et al., 1990; Ahmed et al., 2002) . Whilst EAE has classically been assessed using a subjectively scored scale of paralysis (Table 1 ; Fig. 1A ) (Baker et al., 1990; Smith et al., 2000; Lo et al., 2002) , accumulating residual de®cit could be quantitatively demonstrated through assessment of mobility of remission animals in an open-®eld activity chamber (Fig. 1B) . Whilst ABH mice remitted to exhibit more immobility after one episode of paralysis (P < 0.001; clinical score 0.5), movement activity was further reduced (P < 0.001) after three to four episodes (clinical grade 2.5±3), where animals had chronically developed residual hind limb paresis upon recovery from relapsing paralytic episodes (Fig. 1B) . This immobility was associated with accumulating axonal loss, which could be quantitatively assessed using a neuro®lament ELISA ( Fig. 2A) , and demonstrated histologically ( Fig. 2B and C) .
The cannabinoid system regulates EAE-induced neurodegeneration
Wild-type (ABH) and congenic wild-type homozygous (ABH.Cnr1+/+), heterozygotes (ABH.Cnr1+/±) and CB 1 -de®cient (ABH.Cnr1±/±) mice developed EAE with comparable incidence, severity and onset (Table 1 ). There was, however, an increased frequency (>5%) of EAE-induced mortality in CB 1 -de®cient mice and also in heterozygotes, which have reduced CB 1 expression (Selley et al., 2001) . However, most strikingly CB 1 -de®cient mice exhibited signi®cantly (P < 0.05) more immobility and residual paresis ( Fig. 1 ) and axonal pathology ( Fig. 2A and D±F) than wildtype mice following recovery after the ®rst paralytic episode. These animals relapse and accumulate more de®cits that rapidly reach an acceptable severity limit, including the development of permanent hindlimb paralysis. Consistent with the enhanced neurodegeneration after a single attack, spasticity developed early in ABH.Cnr1±/± mice, which in wild-type ABH mice usually only occurs after three to four attacks . Injection of wild-type mice with the CB 1 antagonist (twice daily with 5 mg/kg rimonabant i.p. from onset; n = 8) induced greater mortality than usually occurs (<5%). However, using clinical signs of remission, the level of neurodegeneration was not as consistent as that found in CB 1 -de®cient animals (data not shown). Although multiple pathways contribute to axonal damage in EAE, the ®nal effector mechanism in neuronal death is probably toxic ion in¯uxes (Ca 2+ ) and caspase-3-mediated apoptosis (Ahmed et al., 2002) , and consistent with this, ABH.Cnr1±/± mice exhibited signi®-cantly (P < 0.001) elevated levels of active caspase-3 during acute-phase EAE compared with wild-type ABH.Cnr1±/± mice, although levels of caspase-1 activity were comparable (Fig. 2F ). Caspase-3 could be detected immunocytochemically in dying axons and these axons demonstrated many transections, which is a feature of multiple sclerosis (Trapp et al., 1998) (Fig. 2D and E) . Therefore, neurodegeneration is clearly elevated in CB 1 -de®cient mice following in¯amma-tory insults, suggesting that CB 1 agonism should have neuroprotective potential in CB 1 -wild-type animals, in addition to controlling neurological symptoms such as tremor and spasticity .
Exogenous CB 1 agonism is neuroprotective in in¯ammatory CNS disease
In CREAE in ABH mice, the neurological de®cit accumulates slowly over a number of months and multi-focal lesions can occur anywhere along the neuroaxis (Baker et al., 1990) , complicating assessment and treatment of neurodegeneration, especially as limited quantities of D 9 -THC were available for study. In contrast, neurodegeneration is restricted to a focal site and develops rapidly in EAU. Following sensitization of B10.RIII mice with IRBP 153±180 peptide, the neuroretina is almost completely destroyed within 14±16 days (Hankey et al., 2001) (Fig. 3A±E ), again associated with caspase-3-induced neuronal pathology (not shown). CB 1 receptor agonism with either R(+)-WIN-55,212-2 ( Figs 3C and 4A) , at doses that demonstrated no immunosuppressive effect in EAE (vehicle: n = 9/9, clinical score 3.3 T 0.4, day of onset 17.6 T 1.2; compared with 5 mg/kg i.p. R(+)-WIN 55,212-2 from day 10±22, n = 7/8, clinical score 3.4 T 0.5, day of onset 17.3 T 1.8), and D 9 -THC signi®cantly inhibited photoreceptor damage, without any apparent inhibition of in¯ammatory in®ltrate ( Figs 3E and 4B ). Therefore, CB 1 agonism can mediate neuroprotection during in¯ammatory insults.
Cannabinoids regulate/inhibit glutamate excitotoxicity
Although immunosuppression, shown by a reduction in the degree of in®ltrate, was not evident following treatment with R(+)-WIN-55, 212±2 or D 9 -THC (Fig. 3) shortly before expression of disease, D 9 -THC has been reported to have immunosuppressive effects (Lyman et al., 1989; Wirguin et al., 1994) , which could in¯uence neurodegenerative potential. As glutamate excitotoxicity has been implicated in neuronal damage in this and other EAE models (Achiron et al., 2000; Pitt et al., 2000; Smith et al., 2000) , glutamateinduced excitotoxicity was examined in vitro and following CNS injection of kainic acid in vivo to examine neuro-protective potential in the absence of a compounding immunomodulation. Following in vitro stimulation of NMDA receptors there was a marked (cerebellar) neuronal Ca 2+ in¯ux, which was more pronounced in CB 1 -de®cient mice than in controls, suggesting that the cannabinoid system exhibits tonic control of this response (Fig. 5A ). In addition, the NMDA receptor antagonist (MK-801) was slower at reducing Ca 2+ to basal levels in CB 1 -de®cient mice compared with ABH.Cnr1+/+ wild type, suggesting Ca 2+ dysregulation in the absence of CB 1 receptors had occurred. Exogenous CB 1 agonism by CP55,940 inhibited this NMDA-induced cytosolic Ca 2+ in¯ux in wild-type animals, maximally at 1 mM using these culture conditions, but was relatively ineffective in CB 1 -knockout mice, suggesting that postsynaptic control of NMDA-receptor activation is lost in CB 1 -de®cient mice (Fig. 5A ). The injection of kainic acid (>0.15 nM) into CB 1 -de®cient mice induced seizures and caused mortality, usually within 10 min post-injection, which did not occur in wild-type ABH and ABH congenic wild-type (Fig. 5B ) mice (P < 0.01), despite using 50-fold higher doses of kainic acid. This elevated mortality was also evident in CD1.Cnr1±/± mice (Fig. 5B) , and therefore CB 1 receptors are also clearly regulating ionotropic glutamate receptor activity (Fig. 5) , which has been implicated in neural exocitoxicity.
Discussion
Neurological disability in multiple sclerosis correlates with spinal cord axonal loss (~50±70% in paralysed multiple sclerosis patients) and reduced N-acetyl aspartate (NAA) levels in chronic multiple sclerosis patients (Bjartmar et al., 2000) . This study provides the ®rst and de®nitive evidence that the cannabinoid system controls the development of neurodegeneration, which occurs as a result of in¯ammatory insult of the CNS. This provides a novel avenue for neuroprotection in multiple sclerosis and other neurodegenerative diseases.
In diseases such as EAE and multiple sclerosis, it is unlikely that there is a single route to neurodegenerative events, and these may change during the disease course. The clinical outcome will be determined by the rate that these accumulate and how the genetic background of the individual enables them to adapt to the insult. Whilst axonal loss occurs very early in the course of multiple sclerosis (Filippi et al., 2003) , it can remain clinically silent for some time, and irreversible neurological disability appears to develop when a threshold (15±30% in mice) of axonal loss is reached and compensatory CNS resources are exhausted (Confavreux et al., 2000; Wujek et al., 2002) . In this model, marginal, statistically non-signi®cant axonal loss occurred after the initial neurological attack, assessed here using a novel, relatively rapid neuro®lament ELISA and by changes in NAA levels (Preece et al., 1994) . Once chronic paresis was evident there was signi®cant axonal loss (~40%) as shown here by ELISA and also by magnetic resonance spectroscopy of spinal cord NAA levels (R. A. Page, H. G. Parkes, D. Baker, G. Giovannoni and C. A. Davie, unpublished observations). However, most interestingly, CB 1 -de®cient mice accumulated signi®cant axonal loss (~36%) even after a single acute episode, indicating that the presence of CB 1 was mediating a degree of neuroprotection during autoimmune attack. Surprisingly, analysis of spinal cord axonal content indicated that apparently normal, CB 1 -de®cient ABH mice have fewer spinal nerves than wild-type animals (P < 0.001), which may be re¯ective of CB 1 involvement in neural plasticity during development (Kim and Thayer, 2001) , or there could be inherent neurodegeneration in these animals. This requires further study.
In EAE and, at least initially, in multiple sclerosis axonal damage occurs at least concordantly with in¯ammation (Ferguson et al., 1997; Trapp et al., 1998) , which produces many potentially damaging elements such as cytokines and oxidative stress (Koprowski et al., 1993; Werner et al., 2001; Lock et al., 2002) . Ionotropic glutamate receptor systems can also signal damaging mechanisms, at the blood±brain barrier and within the neural microenvironment, in EAE and multiple sclerosis (Bolton and Paul, 1997; Achiron et al., 2000; Pitt et al., 2000; Smith et al., 2000; Kalkers et al., 2002) . As shown here, cannabinoids can tonically regulate NMDA glutamate receptor activity in vitro and support the in vivo observation that CB 1 regulates NMDA-induced and ischaemic excitotoxicity (Nagayama et al., 1999; ParmentierBatteur et al., 2002) . We also show de®nitively that CB 1 receptor activity regulates kainate glutamate receptor activity in vivo. Cannabinoids also have anti-oxidant properties that could further limit damaging events during in¯ammation (Hampson et al., 1998; Howlett et al., 2002) . In addition, cellular changes such as neural and oligodendrocyte death and gliosis will change the CNS microenvironment, for example through redistribution of ion channels on demyelinated nerves (Foster et al., 1980; Black et al., 2000) , loss of trophic support and the formation of compensatory neural pathways, which may contribute to excitotoxic stress and induce further degeneration. This could amplify as the disease progresses, possibly largely independent of in¯ammation (Compston and Coles, 2002) , and may have similarities to nerve destruction in other neurodegenerative conditions, such as Huntington's chorea, Alzheimer's disease and amyotrophic lateral sclerosis, where nerve loss accumulates slowly. The cannabinoid system acts as a regulator of many different neurotransmitters and ion (K + and particularly Ca 2+ ) channels (Henry and Chavkin, 1995; Twitchell et al., 1997; Howlett et al., 2002) and appears to be particularly important when CNS homeostasis is in imbalance, as occurs in disease . Therefore, CB 1 can act at many levels within the death cascade, which will ultimately lead to toxic ion in¯uxes, cell metabolic failure and activation of death effector molecules, such as caspase-3 (Ahmed et al., 2002) . This would be consistent with the rapid neurodegeneration that accumulates in CB 1 -de®cient mice. This also implicates a role for endocannabinoids in neuroprotection. The nature of the endogenous neuroprotective cannabinoid has yet to be de®nitively resolved and may involve more than one CB 1 -mediated pathway, possibly dependent on the neural circuit involved. Whilst in head trauma it has been suggested that 2-AG may mediate neuroprotection (Panikashvili et al., 2001) , in a similar study anandamide, not 2-AG, was shown to be active (Hansen et al., 2001) . However, as both anandamide and 2-AG are elevated in chronic EAE lesions ) both may participate in endogenous neuroprotective mechanisms. This will be elucidated once suitable agents to dissect these pathways become available.
Previous studies in non-demyelinating EAE models have demonstrated that high-dose D 9 -THC, often administered during the induction process, has clinical disease ameliorating effects, due to prevention of in®ltrate reaching the CNS (Lyman et al., 1989; Wirguin et al., 1994) . Furthermore, D 9 -THC had no effect on the clinical course, which in Lewis rats is usually naturally self-limiting, when treatment was initi- uorescence imaging. The NMDA receptor agonist, NMDA (100 mM), was added at the arrow and the NMDA receptor antagonist, MK-801, was added at the arrowhead. Where indicated, the CB 1 receptor agonist CP55,940 (1 mM) was added 5 min before imaging commenced and was present throughout the experiment. (B) Kainate-induced excitotoxicity in vivo. Halothane anaesthetized animals (n = 5 per group) were intracerebrally injected with 15±0.15 nmol of kainic acid. Rapid (1±10 min) mortality (open blocks) developed in ABH.Cnr1±/± mice compared with the survival (0 out of 5 mortality; shaded blocks) that occurred in wild type (ABH.Cnr1+/+). Seizures consistent with glutamate excitotoxicity were evident. CB 1 knockout animals died within 1±3 min of injection, whereas heterozygotes typically showed adverse effects 5±10 min after injection. Doses lower than the maximal survival dose for each strain were not tested.
ated at disease onset (Lyman et al., 1989) . Acute phase paralysis in most rodent EAE models is rapidly reversed and can occur largely independent of any demyelination and axonal loss, and more probably re¯ects conduction block (Wujek et al., 2002) . Therefore, inhibition of acute phase paralysis (Lyman et al., 1989) may re¯ect inhibition of the immune process that leads to damage in addition to neural effects. Indeed, CB agonists have recently been reported to have immunomodulatory effects in a viral model of multiple sclerosis (Arevalo-Martin et al., 2003; Croxford and Miller, 2003) . Without the use of tissue-speci®c CB 1 conditional knockouts (Marsicano et al., 2002) , it is probably not possible to completely exclude some in¯uence of cannabinoid inhibition of the immune response in the neurodegenerative process. However, in the context of multiple sclerosis, both would be of bene®t for inhibition of disease. The results of this study are important because they suggest that in addition to symptom management, cannabinoids offer the potential to slow the progression of a disease that as yet has no satisfactory treatment. Therefore, if trials are extended to monitor the long-term effects of cannabis use on symptom management, they should be designed to monitor neuronal loss and progression. If CB 1 agonism can be applied whilst limiting the unwanted psychoactive potential, such as through enhancement of endocannabinoid levels , this may provide a new therapeutic route in multiple sclerosis and could be combined with therapies that target the immunological elements of disease. In neurodegenerative diseases including multiple sclerosis, signs appear once signi®cant damage has already accumulated, slowing the degenerative process early following diagnosis may help improve quality of life for many more years.
